Related Experiment Video
Updated: Feb 19, 2026
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Integrative computational, synthetic, experimental evaluation of targeted inhibitors against matrix
Zainab Ahmed Rashid1, Dima A Sabbah2, Kamal Sweidan3
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman, Jordan.
Abstract:
Matrix metalloproteinase-9 (MMP-9) is a zinc-dependent enzyme that degrades the extracellular matrix and is involved in various diseases, including rheumatoid arthritis, atherosclerosis, tumor invasion, and metastasis. Despite the development of inhibitors, none have succeeded in trials. Our goal was to find potential inhibitors to regulate its proteolytic activity. Ligand- and structure-based drug design approaches were explored to identify inhibitors against wild-type (1GKC) and mutant (2OW1) MMP-9. A pharmacophore model was created, and drug-like molecules were prioritized to guide the development of benzamide and 1H-indole-2-carboxamide derivatives. These compounds were synthesized and characterized using ¹H NMR, 13C NMR, and HRMS (ESI). An experimental evaluation assessed their inhibitory potential and IC50 values against MMP-9. Most tested inhibitors fit the pharmacophore model, which consists of three aromatic/hydrophobic spheres and two hydrogen-bond donors/acceptors. Compounds 1, 2, 8, 10, 20, 21, 27, and 29 exhibited significant inhibition (P < 0.0001) of over 60%. Compounds 2 and 20 inhibited growth by over 70%, with IC50 values of 28.59 μM and 30.82 μM, respectively. The IF docking showed strong binding for these, with scores of -9.179 and -10.739 kcal/mol. The alignment between the computational approach and experimental validation reinforces the inhibitor's specificity and potency, confirms the docking model, and suggests that the predicted binding pose represents key biological interactions.
Insights
Researchers identified novel benzamide and 1H-indole-2-carboxamide derivatives as potent inhibitors of matrix metalloproteinase-9 (MMP-9). These compounds show promise for treating diseases linked to MMP-9 activity, like cancer metastasis and arthritis.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Matrix metalloproteinase-9 (MMP-9) is a key enzyme implicated in extracellular matrix degradation and various pathologies, including cancer metastasis and inflammatory diseases.
- Current MMP-9 inhibitors have faced challenges in clinical trials, necessitating the development of novel therapeutic strategies.
- Targeting MMP-9's proteolytic activity is crucial for managing diseases associated with its dysregulation.
Purpose of the Study:
- To identify and develop novel small-molecule inhibitors targeting matrix metalloproteinase-9 (MMP-9).
- To explore ligand- and structure-based drug design approaches for discovering potent MMP-9 inhibitors.
- To synthesize and experimentally validate benzamide and 1H-indole-2-carboxamide derivatives as potential therapeutic agents.
Main Methods:
- Utilized pharmacophore modeling and drug-like molecule prioritization for inhibitor design.
- Synthesized benzamide and 1H-indole-2-carboxamide derivatives.
- Characterized compounds using NMR spectroscopy (¹H, ¹³C) and HRMS (ESI).
- Assessed inhibitory potential and IC50 values against wild-type and mutant MMP-9.
- Performed IF docking to evaluate binding affinity and interactions.
Main Results:
- Most synthesized compounds exhibited significant MMP-9 inhibition (>60%), with several fitting the established pharmacophore model.
- Compounds 2 and 20 demonstrated potent inhibition (>70%) with IC50 values of 28.59 μM and 30.82 μM, respectively.
- IF docking revealed strong binding affinities for compounds 2 and 20, with scores of -9.179 and -10.739 kcal/mol, respectively.
- Experimental results aligned well with computational predictions, confirming inhibitor specificity and potency.
Conclusions:
- The developed benzamide and 1H-indole-2-carboxamide derivatives represent promising lead compounds for MMP-9 inhibition.
- The study validates the combined computational and experimental approach for designing targeted enzyme inhibitors.
- These findings offer a foundation for further development of MMP-9 inhibitors for therapeutic applications in various diseases.
